Ueki T, Okamoto E, Takeuchi M, Fujimoto J
First Department of Surgery, Hyogo College of Medicine.
Nihon Rinsho. 2001 Jan;59(1):152-6.
Liver cirrhosis is the irreversible end result of chronic liver disease, characterized by diffuse disorganization of the normal hepatic structure of regenerative nodules and fibrotic tissue. It is associated with prominent morbidity and mortality, and is induced by many factors. The ideal strategy for the treatment of liver cirrhosis should include prevention of fibrogenesis, stimulation of hepatocyte mitosis, and reorganization of the liver architecture. We have developed a novel gene therapy approach for rat liver cirrhosis by muscle-directed gene transfer of hepatocyte growth factor(HGF). HGF gene transduction inhibited fibrogenesis and hepatocyte apoptosis, and also produced resolution of fibrosis in the cirrhotic liver. Thus, HGF gene therapy may be potentially useful for the treatment of patients with liver cirrhosis, which is otherwise fatal and untreatable by conventional therapy.
肝硬化是慢性肝病的不可逆终末结果，其特征为正常肝结构的弥漫性紊乱，形成再生结节和纤维化组织。它与显著的发病率和死亡率相关，由多种因素诱发。肝硬化的理想治疗策略应包括预防纤维生成、刺激肝细胞有丝分裂以及肝脏结构的重组。我们通过肌肉导向的肝细胞生长因子（HGF）基因转移，开发了一种针对大鼠肝硬化的新型基因治疗方法。HGF基因转导抑制了纤维生成和肝细胞凋亡，还使肝硬化肝脏的纤维化得到缓解。因此，HGF基因治疗可能对肝硬化患者的治疗具有潜在作用，而肝硬化在其他情况下是致命的且无法通过传统疗法治愈。
